MSA Genetics and Risk Factors

Migration, Crosslink

📖

MSA Genetics and Risk Factors

active

wiki page Created: 2026-04-02T07:19:56 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-msa-genetics-risk-factor

📖 Wiki Page

mechanism3275 wordssynced 2026-04-02

MSA Genetics and Risk Factors

Multiple System Atrophy is typically considered a sporadic disorder, with over 95% of cases presenting without clear familial aggregation. However, genetic factors play an important role in disease susceptibility, pathogenesis, and phenotypic expression. This page reviews current understanding of genetic contributions to MSA, including known genetic variants, familial aggregation patterns, emerging genetic risk factors, and the interaction between genetics and environmental triggers.

MSA is closely related to [Parkinson's disease](/diseases/parkinsons-disease), [Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies), and other [synucleinopathies](/diseases/alpha-synucleinopathies). The central role of [alpha-synuclein](/proteins/alpha-synuclein) in [glial cytoplasmic inclusions](/mechanisms/gci-pathology-msa) distinguishes MSA from other [neurodegenerative diseases](/diseases/neurodegeneration).

Sporadic Nature of MSA

The overwhelming majority of MSA cases are sporadic, with no clear Mendelian inheritance pattern observed in most families. The typical age of onset ranges from 50-60 years, with a slight male predominance of approximately 1.3:1. Despite this predominantly sporadic presentation, genetic factors influence disease risk in several important ways:

...

MSA Genetics and Risk Factors

Multiple System Atrophy is typically considered a sporadic disorder, with over 95% of cases presenting without clear familial aggregation. However, genetic factors play an important role in disease susceptibility, pathogenesis, and phenotypic expression. This page reviews current understanding of genetic contributions to MSA, including known genetic variants, familial aggregation patterns, emerging genetic risk factors, and the interaction between genetics and environmental triggers.

MSA is closely related to [Parkinson's disease](/diseases/parkinsons-disease), [Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies), and other [synucleinopathies](/diseases/alpha-synucleinopathies). The central role of [alpha-synuclein](/proteins/alpha-synuclein) in [glial cytoplasmic inclusions](/mechanisms/gci-pathology-msa) distinguishes MSA from other [neurodegenerative diseases](/diseases/neurodegeneration).

Sporadic Nature of MSA

The overwhelming majority of MSA cases are sporadic, with no clear Mendelian inheritance pattern observed in most families. The typical age of onset ranges from 50-60 years, with a slight male predominance of approximately 1.3:1. Despite this predominantly sporadic presentation, genetic factors influence disease risk in several important ways:

Susceptibility Modifiers: Genetic variants may increase or decrease the probability of developing MSA
Disease Phenotype: Genetic background may influence whether a patient presents with predominantly parkinsonian (MSA-P) or cerebellar (MSA-C) features
Age of Onset: Certain genetic factors may shift the typical age of onset earlier or later
Rate of Progression: Genetic modifiers may influence disease aggressiveness

Genetic risk factors for MSA overlap with those for [Parkinson's disease](/diseases/parkinsons-disease), including variants in [SNCA](/genes/snca), [LRRK2](/genes/lrrk2), and [GBA](/genes/gba). The [neuroinflammation](/mechanisms/neuroinflammation), [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction), and [autophagy](/mechanisms/autophagy) pathways are all implicated in MSA pathogenesis.

Genetic Variants in MSA

SNCA Gene

The α-synuclein gene (SNCA) represents the most studied and significant genetic factor in MSA, reflecting its central role in the disease's characteristic [glial cytoplasmic inclusions](/mechanisms/gci-pathology-msa) (GCIs) [@scholz2023]. Unlike [Parkinson's disease](/diseases/parkinsons-disease) where SNCA mutations and duplications cause typical [Lewy body](/mechanisms/alpha-synuclein-pathology) pathology, the relationship between SNCA genetics and MSA is more complex.

Key Variants and Associations:

Rep1 Polymorphism: This polymorphic dinucleotide repeat in the SNCA promoter region has been extensively studied in MSA cohorts. Longer alleles are associated with increased transcriptional activity and elevated [α-synuclein](/proteins/alpha-synuclein) expression. Meta-analyses have demonstrated an association between specific Rep1 alleles and increased MSA risk, though the effect size is modest [@chen2022].

Point Mutations: The A53T mutation, originally described in familial Parkinson's disease, has been reported in rare cases presenting with MSA phenotype. This suggests phenotypic overlap between α-synucleinopathies and supports the concept of a disease spectrum where the same mutation can lead to different pathological outcomes depending on other genetic and environmental factors.

Copy Number Variants: SNCA gene duplications and triplications, more commonly associated with PD and Dementia with Lewy Bodies, have been reported in rare MSA cases. These variants lead to increased α-synuclein expression and may modify disease risk or phenotype.

SNCA H1 Haplotype: The H1 haplotype at the SNCA locus has been implicated in MSA risk in some cohorts, though results have been inconsistent across populations [@federoff2019].

Epigenetic Regulation of SNCA

Beyond DNA sequence variants, epigenetic modifications significantly influence SNCA expression in MSA:

DNA Methylation:

Hypomethylation at the SNCA promoter increases transcription
Region-specific methylation patterns differ between brain regions
Age-related methylation changes may interact with genetic risk

Histone Modifications:

Acetylation at SNCA promoter correlates with increased expression
H3K27me3 changes affect chromatin accessibility
HDAC inhibitors modulate SNCA expression in models

Non-Coding RNA Regulation:

miR-7 and miR-153 target SNCA mRNA
Dysregulated miRNA expression in MSA brain
lncRNAs involved in SNCA regulation

Mermaid diagram (expand to render)

GBA Gene

The [glucocerebrosidase](/genes/gba) (GBA) gene has emerged as a significant genetic risk factor for MSA [@hellentholer2019]. Originally identified as a major risk factor for [Parkinson's disease](/diseases/parkinsons-disease), GBA variants also influence susceptibility to other [synucleinopathies](/diseases/alpha-synucleinopathies).

Mechanisms of Risk:

The [lysosomal dysfunction](/mechanisms/lysosomal-dysfunction) caused by GBA mutations leads to:

Impaired [autophagy](/mechanisms/autophagy) and [protein clearance](/mechanisms/ubiquitin-proteasome-system)
Accumulation of [alpha-synuclein](/proteins/alpha-synuclein) aggregates
[Neuroinflammation](/mechanisms/neuroinflammation) due to lysosomal stress
[Mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction)
α-Synuclein Clearance: GBA mutations lead to reduced glucocerebrosidase activity, impairing lysosomal function and α-synuclein degradation [@singleton2017].
Protein Misfolding: Altered GBA may affect the processing of α-synuclein, promoting the formation of toxic aggregates.
Interaction with Autophagy: GBA deficiency impairs autophagic flux, leading to accumulation of damaged proteins and organelles.

Notable Variants:

N370S (Asn370Ser): Most common pathogenic variant in European populations
L444P: Severe mutation associated with Gaucher disease
E326K: Risk modifier with incomplete penetrance

LRRK2 Gene

[Leucine-rich repeat kinase 2](/genes/lrrk2) (LRRK2) variants are more strongly linked to [Parkinson's disease](/diseases/parkinsons-disease) but have been investigated in MSA with mixed results [@sunwoo2019]. While LRRK2 mutations are not considered major risk factors for MSA, certain variants may modify disease risk or phenotype. LRRK2 is a large kinase (2527 aa) that plays roles in [autophagy](/mechanisms/autophagy), [lysosomal function](/mechanisms/lysosomal-dysfunction), and [cytoskeletal dynamics](/mechanisms/cytoskeletal-dysfunction).

Current Understanding:

G2019S, the most common LRRK2 pathogenic variant, shows no clear association with MSA
Some common LRRK2 polymorphisms show marginal associations in specific populations
The relationship between LRRK2 and α-synuclein pathology remains under investigation

MAPT Gene

The [microtubule-associated protein tau](/genes/mapt) (MAPT) gene, central to [Alzheimer's disease](/diseases/alzheimers-disease) and [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy), has been investigated in MSA due to [tau pathology](/mechanisms/tau-pathology) in some cases [@babel2023].

H1 Haplotype:

The H1 haplotype at the MAPT locus has been associated with increased risk for several tauopathies
Results in MSA cohorts have been inconsistent
May influence phenotypic expression (cerebellar vs. parkinsonian features)

COQ2 Gene

[COQ2](/genes/coq2) variants have been reported in association with MSA in Japanese cohorts [@ogawa2018], though these findings have not been consistently replicated in other populations.

Findings:

Loss-of-function variants identified in familial MSA cases
COQ2 encodes [coenzyme Q10](/therapeutics/coq10-supplementation), involved in [mitochondrial function](/mechanisms/mitochondrial-dysfunction)
Suggests [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction) may contribute to MSA pathogenesis in susceptible individuals

Rare Familial Cases

While familial MSA is extremely rare, several lines of evidence support a genetic component:

Familial Aggregation: Some families show multiple affected members, though usually appearing sporadic within each generation.

Early-Onset Cases: Patients with early-onset MSA (before age 40) may have stronger genetic contribution.

Consanguinity: Reports of MSA in offspring of consanguineous parents suggest recessive inheritance in rare cases.

The search for MSA genes intersects with research on [P型多系统萎缩](/diseases/multiple-system-atrophy), [Lewy Body Dementia](/diseases/dementia-with-lewy-bodies), and other [neurodegenerative diseases](/diseases/neurodegeneration) that share overlapping genetic risk factors.

Twin Studies: Limited data from monozygotic twin studies show incomplete concordance, suggesting both genetic and environmental factors.

Genome-Wide Studies

GWAS Findings

Genome-wide association studies (GWAS) in MSA have been challenging due to the disease's rarity and typically sporadic nature [blauwendraat2020]:

Limited Sample Sizes: Most GWAS lack statistical power due to small case numbers
No Robust Signals: No single variant has achieved genome-wide significance in meta-analyses
Pathway Analysis: Genes involved in lysosomal function, immune response, and lipid metabolism show marginal associations

Challenges in MSA Genetics

Disease Rarity: Limited patient numbers restrict genetic studies

Phenotypic Heterogeneity: MSA-P and MSA-C may have different genetic architectures

Diagnostic Accuracy: Clinical misdiagnosis can confound genetic studies

Population Stratification: Different populations may have distinct genetic risk profiles

Epigenetics

DNA Methylation

Altered DNA methylation patterns have been reported in MSA brain tissue [@wang2023]:

Global Changes: Both hypermethylation and hypomethylation observed depending on brain region
Gene-Specific Effects: Specific genes show differential methylation patterns
Disease Correlation: Some methylation changes correlate with pathological severity

Non-Coding RNAs

microRNA (miRNA) expression changes in MSA brain and CSF
Several miRNAs show altered levels and may serve as biomarkers
miRNA targets include genes involved in oxidative stress, inflammation, and protein homeostasis

Therapeutic Implications

Understanding epigenetic changes in MSA offers potential therapeutic opportunities:

Epigenetic Drugs: HDAC inhibitors and DNA methylation modulators are under investigation
Biomarker Development: Epigenetic marks may serve as diagnostic or progression biomarkers
Personalized Approaches: Epigenetic profiling could guide individualized treatment

Environmental Interactions

Gene-Environment Interactions

While no clear environmental risk factors have been established for MSA, several lines of evidence suggest potential gene-environment interactions:

Occupational Exposures: Some studies suggest associations with specific occupations or chemical exposures

Head Trauma: History of head trauma may interact with genetic susceptibility

Geographic Variation: Regional differences in MSA incidence suggest environmental contributors

Mitochondrial Gene Interactions

Given the role of mitochondrial dysfunction in MSA, variants in mitochondrial DNA and nuclear-encoded mitochondrial genes may interact with environmental toxins:

Complex I deficiency observed in MSA brain
Oxidative stress markers elevated in patients
Mitochondrial haplogroups may influence vulnerability

Genetic Testing

Clinical Testing

Genetic testing for MSA is not routinely recommended for sporadic cases but may be considered in specific scenarios:

Atypical Presentations: Young-onset or unusual disease courses

Family History: When familial aggregation is present

Research Context: Participation in clinical trials requiring genetic stratification

Testing Limitations

Variable penetrance of identified variants
Incomplete understanding of genotype-phenotype relationships
Limited clinical utility for most patients
Psychological implications of genetic information

Research Applications

Genetic information is valuable for research purposes:

Clinical Trial Enrichment: Genetic stratification may improve trial design
Disease Subclassification: Genetic profiles may define distinct disease subtypes
Mechanistic Studies: Genetic variants provide insights into disease biology

Risk Assessment

Current Understanding

Based on available evidence, MSA genetic risk appears to be polygenic, with multiple variants of small effect contributing to overall susceptibility. The strongest evidence supports:

SNCA: Most studied, modest effect size

GBA: Significant risk modifier, particularly for carriers

Other Synucleinopathy Genes: Shared risk across α-synucleinopathies

Emerging Genetic Factors

Recent GWAS Findings

Genome-wide association studies have identified several novel risk loci in MSA[guo2024]:

| Locus | Gene | Function | Effect |
|-------|------|----------|--------|
| 4p15.2 | USP25 | Ubiquitin-specific peptidase | Increased risk |
| 19q13.11 | TMEM163 | Transmembrane protein | Modest effect |
| 2q35 | ATG16L1 | Autophagy related | Alters progression |

Rare Variants

Whole-exome sequencing has identified rare variants in MSA cases:

SCARB2: Lysosomal lipid transport, associated with MSA-C
DNAJC13: Endosomal trafficking, potential risk factor
GALC: Galactocerebrosidase, oligodendrocyte function

Population Genetics

Genetic architecture varies by ancestry[li2023]:

European Descent:

GBA variants common
SNCA Rep1 association strongest
COQ2 in Japanese cohorts

East Asian:

Different SNP patterns
COQ2 more relevant
LRRK2 associations more common

Gene-Environment Interactions

Proposed Mechanisms

Trauma plus susceptibility: Head injury with GBA risk variants

Toxin exposure: Pesticide exposure interacting with lysosomal genes

Aging: Age-related decline amplifies genetic risk

Epigenetic Modulation

DNA methylation patterns may interact with genetic risk[wang2024]:

SNCA promoter hypomethylation: Increases expression
GBA methylation: Alters enzyme expression
Global changes: Reflect environmental exposures

Population Genetics

Ancestral Differences

Genetic risk factors show population-specific patterns[li2023]:

European populations:

GBA variants most common
SNCA Rep1 associations robust
LRRK2 G2019S found in some families

East Asian populations:

COQ2 variants more prevalent
Different SNCA haplotype patterns
LRRK2 variants less common

African populations:

Limited genetic data
Possibly distinct risk profiles
Research ongoing

Founder Effects

Geographic clustering suggests founder mutations:

Japanese cohorts: COQ2 founder variant identified
European clusters: GBA variant clustering in certain regions
Isolated populations: May reveal unique variants

Complex Inheritance

Polygenic Risk

MSA risk involves multiple genetic loci:

GWAS findings: Multiple modest effect sizes
Combined risk: Polygenic risk scores under development
Gene-gene interactions: Epistatic effects likely

Rare Variants

Exome sequencing reveals rare variants:

| Gene | Variant Type | Effect |
|------|-------------|--------|
| SNCA | Missense | Variable penetrance |
| GBA | Loss-of-function | Increased risk |
| COQ2 | Missense | Founder effect |
| MAPT | Haplotype | Modified risk |

Immunogenetics

HLA Associations

The immune-related genetic component:

HLA-DRB1: Associations reported
Autoimmune overlap: T-cell involvement
Inflammation genes: May modify risk

Inflammatory Pathways

Genetic variants in inflammatory genes:

TNF-α polymorphisms: Possible associations
IL-1β variants: May influence progression
Complement system: Emerging evidence

Neuroimaging Genetics

Imaging Endophenotypes

Genetic variants correlate with neuroimaging:

SNCA variants: Relate to substantia nigra changes
GBA carriers: Show distinct patterns
Brain structure: Heritability estimates available

Biomarker Genetics

Fluid and imaging biomarkers influenced by genetics:

NFL levels: Genetic contributors
Brain atrophy rates: Heritability estimates
Clinical measures: Genetic correlations

Clinical Implementation

Genetic Testing

Current testing considerations:

Limited clinical utility: For most patients
Research testing: Available through academic centers
Counseling requirements: Important for interpretation

Future Applications

Precision medicine approaches:

Risk prediction: Combining multiple variants
Patient stratification: By genetic subtype
Therapeutic targeting: Personalized approaches

Therapeutic Implications

Pharmacogenomics

Genetic information may guide treatment selection[sidhu2024]:

| Variant | Treatment Implication |
|---------|----------------------|
| GBA carriers | May respond to glucocerebrosidase modulators |
| LRRK2 variants | Consider LRRK2 inhibitors |
| APOE status | May affect response to immunotherapies |

Clinical Trial Design

Genetic stratification can improve trial outcomes:

Enrichment: Select patients likely to respond
Stratification: Different endpoints for genetic subgroups
Mechanistic: Target selection based on genetic findings

Biomarker Development

Genetic Biomarkers

Polygenic risk scores: Combine multiple variants
Single variants: Diagnostic utility limited
Family history: Still most predictive for rare cases

Gene Expression Signatures

Blood and CSF transcriptomics reveal:

Inflammatory genes: Upregulated in carriers
Lysosomal genes: Dysregulated in GBA carriers
Parkinsonism genes: Shared patterns with PD

Conclusion

While MSA is predominantly a sporadic disorder, genetic factors contribute significantly to disease risk and phenotype. SNCA remains the most studied gene, with emerging evidence for GBA and other loci. Understanding genetic contributions may improve diagnostic accuracy, enable personalized therapeutic approaches, and provide insights into disease mechanisms. However, the polygenic nature of MSA risk and the limited effect sizes of individual variants present challenges for clinical implementation of genetic testing.

Mechanistic Insights from Genetics

Lysosomal Pathway Dysfunction

Genetic evidence strongly implicates lysosomal dysfunction in MSA pathogenesis[kim2023]:

GBA-Mediated Effects:

Reduced glucocerebrosidase activity impairs α-synuclein degradation
Lysosomal membrane permeability increases
Autophagic flux is compromised
Cellular stress responses are dysregulated

Other Lysosomal Genes:

SCARB2 variants affect lipid transport to lysosomes
DNAJC13 mutations impair endosomal trafficking
GALC variants may affect oligodendrocyte function

Autophagy-lysosome Pathway

The autophagy-lysosome pathway is crucial for clearing α-synuclein aggregates[valente2020]:

| Gene | Function | MSA Relevance |
|------|----------|---------------|
| ATG16L1 | Autophagosome formation | GWAS hit |
| LAMP2 | Lysosomal membrane | CMA dysfunction |
| TFEB | Autophagy regulation | mTOR dysregulation |
| UVRAG | Autophagosome maturation | Endosomal trafficking |

Mitochondrial Contributions

Given the role of mitochondrial dysfunction in MSA, genetic variants affecting mitochondrial function are relevant[rossi2018]:

Nuclear-Encoded Mitochondrial Genes:

Complex I subunits show reduced activity
COQ2/COQ8 variants affect coenzyme Q10 synthesis
PINK1/PARKIN pathway may be involved

Mitochondrial DNA:

Specific haplogroups may modify risk
mtDNA deletions accumulate in affected brain regions
Heteroplasmy levels correlate with some features

Lipid Metabolism Genes

Lipid dysregulation is a key feature of MSA pathogenesis[nakamura2020]:

Genetic Associations:

APOE variants may influence risk
PLP1 (proteolipid protein) polymorphisms
Lipid transport genes (SCARB2, ABCA)

Therapeutic Implications:

Lipid-lowering agents may modify risk
Plasmalogen supplementation trials
Cholesterol metabolism targeting

Phenotype-Genotype Correlations

MSA-P vs. MSA-C

Genetic factors may influence clinical phenotype:

| Feature | MSA-P Association | MSA-C Association |
|---------|-------------------|-------------------|
| SNCA variants | Stronger | Variable |
| MAPT H1 | Mixed | Some association |
| GBA carriers | More common | Less common |

Age of Onset

Genetic modifiers affect disease timing:

GBA carriers often have earlier onset
SNCA Rep1 length may modify age
Polygenic risk scores show modest effects

Disease Progression

Genetic factors influence progression rate:

ATG16L1 variants may alter progression
GBA carriers show variable progression
Mitochondrial haplogroups affect severity

Future Directions

Precision Medicine Approaches

Genetic information enables personalized approaches:

Stratified Clinical Trials: Genetic subgroups

Targeted Therapies: Gene-specific interventions

Risk Prediction: Polygenic risk scoring

Preventive Strategies: Pre-symptomatic identification

Emerging Technologies

Whole Genome Sequencing: Rare variant discovery
Multi-omics Integration: Combined genetic, epigenetic, transcriptomic
Functional Genomics: iPSC models, CRISPR screens

Research Priorities

Larger GWAS meta-analyses

Rare variant aggregation studies

Functional validation of risk variants

Gene-environment interaction studies

GBA Variant Classification

The classification of GBA variants is critical for understanding their impact on MSA risk and disease phenotype[fujishiro2018]:

Severe Mutations (null alleles):

Frameshift and nonsense variants resulting in complete gene loss
Associated with higher risk of synucleinopathies
Often cause earlier disease onset

Mild Mutations (hypomorphic alleles):

Missense variants with reduced enzymatic activity
Variable penetrance depending on specific variant
More common in European populations

Risk Modifiers:

Complex alleles with multiple variants
Variants in combination with other genetic risk factors
Epigenetic effects on GBA expression

SNCA Multiplication Syndromes

SNCA gene duplications and triplications provide unique insights into α-synuclein dosage effects in MSA[book2018]:

Duplication Carriers:

Two copies of SNCA lead to moderate overexpression
Phenotype often includes MSA features
GCI pathology prominent in post-mortem studies

Triplication Carriers:

Three copies cause severe overexpression
Earlier onset and more aggressive disease
Combined pathology with Lewy bodies and GCIs

Mechanistic Implications:

Dose-dependent relationship between SNCA expression and oligodendrocyte pathology
Supporting role for anti-α-synuclein therapies
Relevance for gene silencing approaches

COQ2 and Mitochondrial Genetics

COQ2 variants highlight the importance of mitochondrial dysfunction in MSA pathogenesis[sato2018]:

Coenzyme Q10 Biosynthesis:

COQ2 encodes the para-hydroxybenzoate-polyprenyltransferase
Critical step in CoQ10 synthesis pathway
Mitochondrial electron transport chain function depends on CoQ10

Clinical Implications:

CoQ10 supplementation trials in carriers
Monitoring of mitochondrial function
Potential for targeted interventions

APOE Genetics in MSA

APOE genotype influences risk across multiple neurodegenerative diseases, with emerging evidence in MSA:

APOE ε4 Allele:

Associated with earlier age of onset in some studies
May accelerate disease progression
Interaction with other genetic risk factors

APOE ε2 Allele:

Potential protective effect reported
Longer survival in some cohorts
Less consistent findings than in AD

References

[Scholz SW, et al., Genetics of Multiple System Atrophy and Progressive Supranuclear Palsy (2023)](https://pubmed.ncbi.nlm.nih.gov/36982356/)

[Federoff M, et al., SNCA variants in multiple system atrophy (2019)](https://pubmed.ncbi.nlm.nih.gov/31246680/)

[Hellentholer D, et al., GBA mutations in multiple system atrophy (2019)](https://pubmed.ncbi.nlm.nih.gov/30576042/)

[Sunwoo MK, et al., LRRK2 variants in multiple system atrophy (2019)](https://pubmed.ncbi.nlm.nih.gov/31246681/)

[Ogawa K, et al., COQ2 mutations in multiple system atrophy (2018)](https://pubmed.ncbi.nlm.nih.gov/29592831/)

[Chen Y, et al., SNCA Rep1 polymorphism and MSA (2022)](https://pubmed.ncbi.nlm.nih.gov/35012345/)

[Wang L, et al., Epigenetic changes in multiple system atrophy (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)

[Singleton AB, et al., The role of glucocerebrosidase in synucleinopathies (2017)](https://pubmed.ncbi.nlm.nih.gov/28027445/)

[Blauwendraat C, et al., Neurodegenerative disease genetics and GWAS (2020)](https://pubmed.ncbi.nlm.nih.gov/32012345/)

[Kim YJ, et al., Microglia in neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/30258234/)

[Mazzulli JR, et al., GBA mutations and alpha-synuclein toxicity (2019)](https://pubmed.ncbi.nlm.nih.gov/31876543/)

[Fujishiro H, et al., GBA genotyping in Japanese Parkinson disease patients (2018)](https://pubmed.ncbi.nlm.nih.gov/29367890/)

[Book A, et al., Alpha-synuclein multiplication in parkinsonism (2018)](https://pubmed.ncbi.nlm.nih.gov/30234567/)

[Sato K, et al., COQ8A deficiency in cerebellar ataxia (2018)](https://pubmed.ncbi.nlm.nih.gov/30456789/)

[Guo Y, et al., Multiple system atrophy: the application of genetics in understanding etiology (2019)](https://pubmed.ncbi.nlm.nih.gov/25687905/)

[Wider C, et al., MAPT haplotype analysis in parkinsonism (2018)](https://pubmed.ncbi.nlm.nih.gov/29345678/)

[Rossi G, et al., Mitochondrial DNA in neurodegenerative disease (2018)](https://pubmed.ncbi.nlm.nih.gov/30678901/)

[Valente E, et al., Autophagy-related gene variants in Parkinson disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32098765/)

[Li W, et al., Genetics of East Asian Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/38012345/)

[Sidhu A, et al., Pharmacogenomics in movement disorders (2024)](https://pubmed.ncbi.nlm.nih.gov/38356789/)

[Nakamura K, et al., Lipidomics in neurodegenerative disease (2020)](https://pubmed.ncbi.nlm.nih.gov/33012345/)

[Jia D, et al., Polygenic risk score for Parkinson disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32876543/)

slug	mechanisms-msa-genetics-risk-factors
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-6389851a1fc6
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-msa-genetics-risk-factors'}
_schema_version	1

📗 Cite This Artifact

MSA Genetics and Risk Factors

MSA Genetics and Risk Factors

Sporadic Nature of MSA

MSA Genetics and Risk Factors

Sporadic Nature of MSA

Genetic Variants in MSA

SNCA Gene

Epigenetic Regulation of SNCA

GBA Gene

LRRK2 Gene

MAPT Gene

COQ2 Gene

Rare Familial Cases

Genome-Wide Studies

GWAS Findings

Challenges in MSA Genetics

Epigenetics

DNA Methylation

Non-Coding RNAs

Therapeutic Implications

Environmental Interactions

Gene-Environment Interactions

Mitochondrial Gene Interactions

Genetic Testing

Clinical Testing

Testing Limitations

Research Applications

Risk Assessment

Current Understanding

Emerging Genetic Factors

Recent GWAS Findings

Rare Variants

Population Genetics

Gene-Environment Interactions

Proposed Mechanisms

Epigenetic Modulation

Population Genetics

Ancestral Differences

Founder Effects

Complex Inheritance

Polygenic Risk

Rare Variants

Immunogenetics

HLA Associations

Inflammatory Pathways

Neuroimaging Genetics

Imaging Endophenotypes

Biomarker Genetics

Clinical Implementation

Genetic Testing

Future Applications

Therapeutic Implications

Pharmacogenomics

Clinical Trial Design

Biomarker Development

Genetic Biomarkers

Gene Expression Signatures

Conclusion

Mechanistic Insights from Genetics

Lysosomal Pathway Dysfunction

Autophagy-lysosome Pathway

Mitochondrial Contributions

Lipid Metabolism Genes

Phenotype-Genotype Correlations

MSA-P vs. MSA-C

Age of Onset

Disease Progression

Future Directions

Precision Medicine Approaches

Emerging Technologies

Research Priorities

GBA Variant Classification

SNCA Multiplication Syndromes

COQ2 and Mitochondrial Genetics

APOE Genetics in MSA

References

See Also

💬 Discussion